These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23259666)

  • 21. Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics.
    Chua K; Howden BP
    Curr Opin Infect Dis; 2009 Dec; 22(6):525-34. PubMed ID: 19738465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A lipopolysaccharide binding heteromultivalent dendrimer nanoplatform for Gram negative cell targeting.
    Wong PT; Tang S; Tang K; Coulter A; Mukherjee J; Gam K; Baker JR; Choi SK
    J Mater Chem B; 2015 Feb; 3(6):1149-1156. PubMed ID: 32261994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of an inducible vancomycin resistance system in Streptomyces coelicolor reveals a novel gene (vanK) required for drug resistance.
    Hong HJ; Hutchings MI; Neu JM; Wright GD; Paget MS; Buttner MJ
    Mol Microbiol; 2004 May; 52(4):1107-21. PubMed ID: 15130128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multivalent approach to drug discovery for novel antibiotics.
    Long DD; Aggen JB; Christensen BG; Judice JK; Hegde SS; Kaniga K; Krause KM; Linsell MS; Moran EJ; Pace JL
    J Antibiot (Tokyo); 2008 Oct; 61(10):595-602. PubMed ID: 19168973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting cancer cells with biotin-dendrimer conjugates.
    Yang W; Cheng Y; Xu T; Wang X; Wen LP
    Eur J Med Chem; 2009 Feb; 44(2):862-8. PubMed ID: 18550227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a novel series of semisynthetic vancomycin derivatives effective against vancomycin-resistant bacteria.
    Nakama Y; Yoshida O; Yoda M; Araki K; Sawada Y; Nakamura J; Xu S; Miura K; Maki H; Arimoto H
    J Med Chem; 2010 Mar; 53(6):2528-33. PubMed ID: 20180534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular interactions between glycopeptide vancomycin and bacterial cell wall peptide analogues.
    Xing B; Jiang T; Wu X; Liew R; Zhou J; Zhang D; Yeow EK
    Chemistry; 2011 Dec; 17(50):14170-7. PubMed ID: 22083883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vancomycin-dendrimer based multivalent magnetic separation nanoplatforms combined with multiplex quantitative PCR assay for detecting pathogenic bacteria in human blood.
    Feng X; Meng X; Xiao F; Aguilar ZP; Xu H
    Talanta; 2021 Apr; 225():121953. PubMed ID: 33592708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Affinity capture using vancomycin-bound magnetic nanoparticles for the MALDI-MS analysis of bacteria.
    Lin YS; Tsai PJ; Weng MF; Chen YC
    Anal Chem; 2005 Mar; 77(6):1753-60. PubMed ID: 15762582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conformational analysis of bacterial cell wall peptides indicates how particular conformations have influenced the evolution of penicillin-binding proteins, beta-lactam antibiotics and antibiotic resistance mechanisms.
    Grail BM; Payne JW
    J Mol Recognit; 2002; 15(3):113-25. PubMed ID: 12203837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective cleavage of D-Ala-D-Lac by small molecules: re-sensitizing resistant bacteria to vancomycin.
    Chiosis G; Boneca IG
    Science; 2001 Aug; 293(5534):1484-7. PubMed ID: 11520986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multivalent artificial opsonin for the recognition and phagocytosis of Gram-positive bacteria by human phagocytes.
    Katzenmeyer KN; Bryers JD
    Biomaterials; 2011 Jun; 32(16):4042-51. PubMed ID: 21388677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vancomycin-resistant Staphylococcus aureus].
    Rodríguez CA; Vesga O
    Biomedica; 2005 Dec; 25(4):575-87. PubMed ID: 16433184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating binding avidities of populations of heterogeneous multivalent ligand-functionalized nanoparticles.
    Li MH; Choi SK; Leroueil PR; Baker JR
    ACS Nano; 2014 Jun; 8(6):5600-9. PubMed ID: 24810868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and characterization of G5 PAMAM dendrimer containing daunorubicin for targeting cancer cells.
    Yue Y; Eun JS; Lee MK; Seo SY
    Arch Pharm Res; 2012 Feb; 35(2):343-9. PubMed ID: 22370789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vancomycin resistance: small molecule approaches targeting the bacterial cell wall biosynthesis.
    Süssmuth RD
    Chembiochem; 2002 Apr; 3(4):295-8. PubMed ID: 11933229
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative proteomic analysis of Staphylococcus aureus strains with differences in resistance to the cell wall-targeting antibiotic vancomycin.
    Pieper R; Gatlin-Bunai CL; Mongodin EF; Parmar PP; Huang ST; Clark DJ; Fleischmann RD; Gill SR; Peterson SN
    Proteomics; 2006 Aug; 6(15):4246-58. PubMed ID: 16826566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
    Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
    Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.